Back to top
more

Cabaletta Bio (CABA)

(Delayed Data from NSDQ)

$11.01 USD

11.01
2,916,597

-1.17 (-9.61%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $10.99 -0.02 (-0.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Are Medical Stocks Lagging Cabaletta Bio (CABA) This Year?

by Zacks Equity Research

Here is how Cabaletta Bio, Inc. (CABA) and KalVista Pharmaceuticals, Inc. (KALV) have performed compared to their sector so far this year.

QIAGEN (QGEN) Extends the AI-Powered QCI Interpret Software

by Zacks Equity Research

QIAGEN's (QGEN) NGS interpretation software, QCI Interpret, now covers the whole exome due to additional AI capabilities.

What Makes Cabaletta Bio, Inc. (CABA) a Good Fit for 'Trend Investing'

by Zacks Equity Research

Cabaletta Bio, Inc. (CABA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Cabaletta Bio, Inc. (CABA) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

Cabaletta Bio, Inc. (CABA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Wall Street Analysts Believe Cabaletta Bio, Inc. (CABA) Could Rally 41.61%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 41.6% upside potential for Cabaletta Bio, Inc. (CABA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Recent Price Trend in Cabaletta Bio, Inc. (CABA) is Your Friend, Here's Why

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Cabaletta Bio, Inc. (CABA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Does Cabaletta Bio, Inc. (CABA) Have the Potential to Rally 27.85% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 27.9% in Cabaletta Bio, Inc. (CABA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Here's Why Cabaletta Bio, Inc. (CABA) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does Cabaletta Bio, Inc. (CABA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Novo Nordisk (NVO) Q4 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Novo Nordisk (NVO) reports mixed results for Q4 as earnings beat estimates but sales miss on the same. Sales are aided by growth in Diabetes and Obesity Care on higher GLP-1 revenues.

Is Aurora Cannabis (ACB) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Aurora Cannabis Inc. (ACB) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.

Cabaletta Bio, Inc. (CABA) Is a Great Choice for 'Trend' Investors, Here's Why

by Zacks Equity Research

Cabaletta Bio, Inc. (CABA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

The Zacks Analyst Blog Highlights AVEO Pharmaceuticals, Cabaletta Bio, Verona Pharma and Wave Life Sciences

by Zacks Equity Research

AVEO Pharmaceuticals, Cabaletta Bio, Verona Pharma and Wave Life Sciences are included in this Analyst Blog.

4 Drug Stocks That More Than Doubled This Year

by Zacks Equity Research

We present four biotech stocks, AVEO, CABA, VRNA and WVE, which despite the current volatile market, have provided more than twice the returns in 2022.

Is Neuronetics (STIM) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Neuronetics (STIM) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.

Can Cabaletta Bio, Inc. (CABA) Climb 60% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for Cabaletta Bio, Inc. (CABA) points to a 60% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Is Merck & Co. (MRK) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Merck (MRK) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.

What Makes Cabaletta Bio, Inc. (CABA) a New Buy Stock

by Zacks Equity Research

Cabaletta Bio, Inc. (CABA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Down 63.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Cabaletta Bio, Inc. (CABA)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Cabaletta Bio, Inc. (CABA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Wall Street Analysts Predict a 52% Upside in Cabaletta Bio, Inc. (CABA): Here's What You Should Know

by Zacks Equity Research

The mean of analysts' price targets for Cabaletta Bio, Inc. (CABA) points to a 51.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks.com featured highlights include: UFP Industries, Cabaletta Bio, Alto Ingredients, Ribbon Communications and Software Acquisition Group

by Zacks Equity Research

Zacks.com featured highlights include: UFP Industries, Cabaletta Bio, Alto Ingredients, Ribbon Communications and Software Acquisition Group

Shrabana Mukherjee headshot

5 Stocks for Solid Returns as Analysts Initiate Coverage

by Shrabana Mukherjee

Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like UFP Industries (UFPI), Cabaletta Bio (CABA), Alto (PEIX), Ribbon (RBBN) and Software Acquisition (CURI).

Cabaletta Bio, Inc. (CABA) Moves to Strong Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Cabaletta Bio, Inc. (CABA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Tirthankar Chakraborty headshot

New Strong Buy Stocks for April 27th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:

Cabaletta Bio, Inc. (CABA) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research

Cabaletta Bio, Inc. (CABA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.